The high malignant potential BCT (i.e. IPMN and MCN) have been shown to have the mutated KRAS more frequently [69], [70] and we show these lesions had no significant difference in miR-126 expression when compared to PDAC. Here, KRAS is linked to pancreatic intraductal papillary-mucinous neoplasm.